Pfizer CEO Bails On EU Testimony After Report Highlights ''Secretive'' Vaccine Deal Pfizer CEO Albert Bourla has bailed on an appointment to testify before the European Parliament''s special committee, where he was expected to face tough questions over secretive vaccine deals , Politico reports. Albert Bourla, the Pfizer chief executive, during a visit last week, at a Pfizer factory in Belgium.Credit…Pool photo by John Thys Bourla was scheduled to appear before the panel on Oct. 10, alongside key officials involved in the EUs vaccine procurement process, in order to discuss how to respond to future pandemics. According to the report, "Other pharmaceutical executives have addressed the committee, including the CEO of Moderna and senior officials from AstraZeneca and Sanofi." Bourla? Not so much. The committee''s chair, Belgian MEP Kathleen Van Brempt, told POLITICO she "deeply regrets" the decision taken by Pfizer. After a visit to BioNTech''s headquarters last week, Van Brempt had said in a written statement that she looked forward to discussions "with other CEOs" including "Mr.
→ Google Traductor
In general, when markets trend lower, it makes sense to invest in blue-chip stocks. They tend to have a low beta and also provide regular cash flows through dividends. Yet, not all blue chips are created equal. Based on macroeconomic or company-specific factors, there are some you want to buy and some blue-chip stocks to sell. For example, blue-chip retailer Target (NYSE: TGT ) sits 45% below its 52-week high, weighed down by inflationary pressures and margin compression. And pharmaceutical giant Pfizer (NYSE: PFE ) is 30% below its high on concerns of a slowdown in growth predominately due to lower Covid-19 vaccine sales. So, investors need to carry out due diligence even with blue chips. Today’s list of blue-chip stocks to sell in October contains popular names that are likely to correct or correct even further. PEP PepsiCo $163.26 COST Costco Wholesale $472.27 FCX Freeport-McMoRan $27.35 OXY Occidental Petroleum $61.43 PepsiCo (PEP) Source: 8ED8 / Shutterstock PepsiCo (NASDAQ: PEP ) stock is up 11% over the past year, bucking the broader bear market, and it throws off a healthy 2.7% dividend yield.
→ Google Traductor
Global Blood Therapeutics (GBT) expects to consummate its $5.4B deal with Pfizer (PFE) on Oct. 5, the sickle cell disease drugmaker said in a regulatory filing on Friday
→ Google Traductor
Pharma giant Pfizer has shelled out nearly US$120 million to acquire a small Australian company claiming to have developed a smartphone app that can accurately diagnose COVID-19 by analyzing the sound of a cough. Initially the system was trained to diagnose pneumonia, but by 2019 the researchers had shown the technology could effectively distinguish asthma, […]
→ Google Traductor
In addition to dramatically increasing work for the biological pharmaceutical industry for companies like Merck, Pfizer, and Eli Lilly, this manufacturer is also growing in automotive, supplying Volvo and Mack trucks, as well as BMW and now Volvo automobiles.
→ Google Traductor
BEIJING: The Indonesian food and drugs agency (BPOM) said on Thursday (Sep 29) it has approved the emergency use of an mRNA COVID-19 vaccine developed by China''s Walvax Biotechnology. It is the first authorisation for a China-developed COVID shot based on the novel mRNA technology, which Pfizer-BioNTech an
→ Google Traductor
BOSTON, MA / ACCESSWIRE / September 29, 2022 / DPS Group , a privately-owned, global engineering, procurement, construction management and validation (EPCMV) firm serving high-tech process industries, today announced that Jim Grunwald, Senior Vice President of U.S. Business Development, has received the Hank Moes Award from the Boston Chapter of the International Society for Pharmaceutical Engineering ( ISPE Boston ). The Hank Moes Award is presented to a Boston Area Chapter member in recognition of a comprehensive body of work and specific accomplishments that are widely recognized as truly extraordinary and of positive and lasting impact on ISPE, the Boston Area Chapter, and the life sciences/biopharmaceutical industry. "Jim has established himself as a presence and a leader in the life sciences industry in the greater Boston Area - it''s unlikely you will meet someone here in the industry who doesn''t know Jim," said Tom Struble, past president of ISPE Boston and director of commissioning, qualification, and validation (CQV) at DPS Group. "His relentless energy and infectious enthusiasm have left a lasting impact on the local biopharma industry, and his stalwart support of ISPE has molded the Boston Area Chapter into the massive success it is today." Jim has a consistent, long-standing, and extraordinary legacy of supporting ISPE, specifically the Boston chapter.
→ Google Traductor
SINGAPORE, Sept 29 — The Health Sciences Authority (HSA) yesterday authorised the use of Pfizer’s Comirnaty Covid-19 vac…
→ Google Traductor
NEW YORK and MAINZ, GERMANY, September 28, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for
→ Google Traductor
New Jersey, USA -- ( SBWIRE ) -- 09/28/2022 -- The latest study released on the Global Clinical Trials Market by AMA Research evaluates market size, trend, and forecast to 2027. The Clinical Trials market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Download Sample Report PDF (Including Full TOC, Table & Figures) @ https://www.advancemarketanalytics.com/sample-report/17830-global-clinical-trials-market#utm_source=SBWireLal Key Players in This Report Include: Charles River Laboratories (United States), Quintiles IMS (United States), Eli Lilly and Company (United States), SGS SA (Switzerland), Paraxel International Corporation (United States), Pfizer Inc. (United States), Novo Nordisk A/S (United States), Clinipace (United States), Laboratory Corporation of America (United States), ICON Plc (Ireland), IQVIA (United States), Pharmaceutical Product Development, LLC(United States), Syneos Health (United States), PRA Health Sciences (United States), Wuxi AppTec (China).
→ Google Traductor
Rockland County has been home to Pfizer for more than 20 years and believes the time is right to expand its research and development capabilities. “Vaccines are one of the primary drivers for Pfizer as never before,” said Steve Bjornson, chief operating officer, at a recent Rockland Business Association (RBA) on Sept. 15 at Hotel […] The post PFIZER IS HERE TO STAY appeared first on Westfair Communications .
→ Google Traductor
Pfizer, Inc. with ticker code (PFE) now have 20 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 75 and 44 with the average target price sitting at 56.81. Now with the previous closing price of 43.83 this is indicating there is a potential upside of 29.6%. The day 50 moving average is 48.21 and the 200 day MA is 51.18. The market capitalisation for the company is $247,449m. You can visit the company''s website by visiting: https://www.pfizer.com [stock_market_widget type="chart" template="basic" color="green" assets="PFE" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $320,729m based on the market concensus. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women''s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
→ Google Traductor
Futures Rebound From 2022 Low After Bank Of England Panics, Restarts Unlimited QE With everything biw breaking, including an explosive move in bond yields in the UK, 10Y yields rising above 4.00%, and Apple "suddenly" realizing there was not enough demand for the latest iteration of its iPhone 5, it was only a matter of time before some central bank somewhere capitulated and pivoted back to QE, and this morning that''s precisely what happened when the BOE delayed the launch of QT and restarted QE " on whatever scale is necessary" on a "temporary and targeted" ( lol ) basis to restore order, which sent UK bond surging (and yields tumbling the most on record going back to 1996 erasing an earlier jump to the the highest since 1998)… ... the pound first surged before falling back as traders realized the UK now has both rate hikes and QE at the same time, the dollar sliding then spiking, the 10Y US TSY yield dipping from 4.00%, the highest level since 1998, and stock futures spiking from fresh 2022 lows, but then fizzling as traders now demand a similar end to QT/restart of QE from the Fed or else they will similarly break the market.
→ Google Traductor
AION Labs, a Rehovot-based consortium formed by Pfizer, Merck, AstraZeneca, Teva and others, sets up company that will help drug firms improve chances of success in clinical trials
→ Google Traductor
The most recent report published by Market Research Inc. indicates that the Cough Remedies Market is likely to accelerate significantly in the next few years. Specialists have studied market drivers, restraints, risks and prospects in the global market. The Cough
→ Google Traductor
Israeli Investigators Find COVID-19 Vaccines Cause Side Effects: Leaked Video Authored by Meiling Lee and Zachary Stieber via The Epoch Times (emphasis ours), Syringes and vials of the Pfizer-BioNTech COVID-19 vaccine in Netanya, Israel, on Jan. 5, 2022. (Jack Guez/AFP via Getty Images) Israeli researchers found some side effects that occurred after COVID-19 vaccination were caused by Pfizer’s vaccine, according to a leaked video . The Israeli Ministry of Health (MoH) commissioned researchers to analyze adverse event reports submitted by Israelis and the researchers presented findings from the new surveillance system in an internal June 2022 meeting, video of which was obtained by an Israeli journalist. Researchers said that the phenomenon of rechallenge—when adverse events reoccur or worsen following additional vaccine doses—proved that some of the events were caused by the vaccine. A positive rechallenge was reported in 10 percent of the women who complained of menstrual issues, according to the researchers, who also identified cases of rechallenge for other adverse events.
→ Google Traductor
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Amniotics, Antengene, Astrazeneca, Bausch + Lomb, Beigene, Biontech, Frontera, Glenmark, Junshi, Keymed, Merck, Pfizer, Veru.
→ Google Traductor
Americans have two options for getting a new omicron-specific Covid booster shot: Pfizer or Moderna. Which one should you get? Here''s what experts say.
→ Google Traductor
Source: Ruslan Ivantsov / Shutterstock.com Wall Street has officially entered a bear market. Macroeconomic headwinds continue to build, including rampant inflation, slowing economic growth and continued geopolitical turmoil. We now have further uncertainty surrounding the stock market following the most recent interest rate hike. As we enter a bear market, investors are searching for alternative investment paths for diversification. Growth names that were the darlings on Wall Street during the pandemic have not been immune to these challenges so far in the year. Even large-capitalization (cap) shares have come under pressure since January. Year-to-date (YTD), the S&P 500 index has so far dropped over 22.9% year-to-date (YTD), while the tech-heavy Nasdaq 100 has declined more than 30.7% during the same period. In the past century, we have had over 25 bear markets on the Street. Most have lasted an average of less than one year. While it may be tempting to sell stocks in the portfolio to minimize losses, panic selling in a bear market often leads to loss of potential profits and even investment capital.
→ Google Traductor
As people acclimatize to the new normal, it’s time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections. Once infected with the less fatal strain, Omicron, people would isolate themselves for a few days and then return to work. By shifting away from its reliance on drug companies, investors must recognize there are vaccine stocks that it’s time to sell. The government cut orders for vaccines and antiviral drugs, which already is hurting vaccine stocks. People realized that the vaccine specific to the Delta variant offered minimal protection against the current strains. As Omicron sub-variants emerge, health organizations will evaluate the effectiveness of bivalent vaccines first. Investors should brace for a sharp drop in vaccine and test kit sales. Those are the vaccine stocks to sell. In addition, companies that depend on antiviral sales risk underperforming. Still, their revenue drop is less severe.
→ Google Traductor
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
→ Google Traductor
Pfizer and BioNtech asked the U.S. Food and Drug Administration on Monday to approve their new Omicron-specific COVID-19 vaccine for children ages 5 to 11.
→ Google Traductor
Pfizer and BioNTech have asked United States health officials to authorize their Omicron-targeting Covid booster vaccine for children.
→ Google Traductor
Pfizer found using ticker (PFE) have now 20 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 75 and 44 calculating the mean target price we have 56.81. Now with the previous closing price of 44.57 this would imply there is a potential upside of 27.5%. The 50 day moving average now sits at 48.37 and the 200 day moving average is 51.22. The market cap for the company is $247,392m. You can visit the company''s website by visiting: https://www.pfizer.com [stock_market_widget type="chart" template="basic" color="green" assets="PFE" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $315,332m based on the market concensus. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women''s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
→ Google Traductor
Pfizer CEO Albert Bourla has tested positive for Covid-19 for the second time in six weeks, despite being vaccinated four times Read Full Article at RT.com
→ Google Traductor
Pfizer Chief Executive Officer Albert Bourla said on Saturday (Sep 24) he had tested positive for COVID-19. "I’m feeling well and symptom free," Bourla said in a statement. Bourla, 60, back in August had contacted COVID and had started a course of the company''s oral COVID-19 antiviral treatment
→ Google Traductor
Pfizer Inc Chief Executive Officer Albert Bourla said on Saturday he had tested positive for COVID-19. “I’m feeling well and symptom free,” Bourla said in a statement. Bourla, 60, back in August had contacted COVID and had started a course of the company’s oral COVID-19 antiviral treatment, Paxlovid. Paxlovid is an antiviral medication that is […]
→ Google Traductor
The U.S. and Pfizer will be lowering their number of global vaccine donations in response to a "reduced demand," though the company says it is still committed to supplying the roughly 1 billion doses that the U.S. has committed to providing. Last year, the Biden administration committed to donating at least 1.1 billion doses of…
→ Google Traductor
Kazi Awal/Insider Pfizer, along with BioNTech, used breakthrough mRNA technology to create its COVID-19 vaccine. The potential of this new tech could transform science, leaders…
→ Google Traductor
The COVID-19 vaccine unlocked the potential of mRNA technology and new ways of approaching problems, a senior vice president told Insider.
→ Google Traductor
Two years ago, I wrote about buying on the dip as an investment strategy for those in the FIRE movement. FIRE stands for Financial Independence, Retire Early, and involves a commitment to both cutting your daily expenses and an accelerated investment strategy. Today, FatFIRE is the “in” retirement concept. FatFIRE takes things a step further. Devotees to this new movement want to be able to “retire with a fat stash” that allows them to live on around $100,000 a year . According to Fortune, FatFIRE split off from FIRE in 2016 when a Reddit user decided cutting his expenses to the bone wasn’t his idea of a good time. And so the subreddit r/fatFIRE was born. Today, it has more than 330,000 members. The downside of FatFIRE is that it’s incredibly unrealistic. Very few people have the skillset to pull it off. Financial planner Dana Menard puts it at around a tenth of the population. If you believe you’re in this cohort, though, here are seven investments to help you with your FatFIRE dreams.
→ Google Traductor
Pfizer (PFE) and the US government have agreed to reduce the number of COVID-19 vaccines the latter will donate to other countries this year to 600M doses from 1B, Bloomberg reported.
→ Google Traductor
Pfizer (PFE) and BioNTech (BNTX) are seeking Swissmedic authorization of a second bivalent COVID-19 vaccine.The updated Comirnaty vaccine contains half mRNA coding for the spike protein…
→ Google Traductor
Pfizer Inc (NYSE: PFE ) would supply up to 6 million courses of its COVID-19 antiviral treatment to NGO Global Fund for low- and middle-income countries. The company said Paxlovid treatment courses would be available for procurement through Global Fund''s COVID-19 Response Mechanism to 132 low- and middle-income countries this … Full story available on Benzinga.com
→ Google Traductor
The U.S. Centers for Disease Control and Prevention ((CDC)) expects to recommend updated COVID-19 booster shots from Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) for children in early…
→ Google Traductor
The U.S. government has made available more than 25M doses of updated COVID-19 booster shots, mostly from Pfizer (PFE)/BioNTech (BNTX), while Moderna (MRNA) is ramping up production,…
→ Google Traductor
From 2Q 2021 to 2Q 2022, Pfizer’s net income increased by 78% YoY to $9.9B. Click here to read why I believe PFE stock has a bright future and is a Buy.
→ Google Traductor
The U.S. government has sent out over 25 million of the updated COVID-19 booster shots, mostly from Pfizer/BioNTech, as production of the Moderna shot continues to ramp up, a federal health agency said Tuesday. Some U.S. pharmacies, including CVS Health and Walgreens Boots Alliance, also reported on Tuesday that government supply of Moderna''s updated shot remains limited, causing appointments for the product to vary across the country. Both CVS and Walgreens said they are working with the government to acquire more Moderna doses and have not seen any supply issues for the Pfizer booster. In August, the U.S. Food and Drug Administration authorized Pfizer''s and Moderna''s updated booster shots that target the dominant BA.4 and BA.5 omicron subvariants, as the country prepares for a broad fall revaccination campaign. According to the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), retail pharmacies will be receiving millions more doses of Moderna this week and production is ramping up. "We anticipate supply will continue to increase in the coming weeks," an ASPR spokesperson told Reuters.
→ Google Traductor
The idea that anyone could have a problem with Joe Biden’s cancer moonshot is unimaginable. After all, who hasn’t had a friend or relative affected by cancer? My dad died from a combination of prostate and bone cancer. Now, you could argue that, at 81, old age might have done him in, regardless of the disease eating away at his body. But, the reality is that so many die much younger than my dad from various forms of cancer. It is a scourge to longevity everywhere. Biden’s cancer moonshot aims to cuts the death rate from cancer in the U.S. by 50% over the next 25 years while improving the experience of those dealing with cancer. I’m 100% for it. I’m sure the drug companies are, too. Forget the old myth that they don’t want to cure cancer. There is a lot of money to be made by eliminating a virus or disease. Who are the companies developing the best cancer moonshots? Below are three possibilities. MRK Merck & Co $86.02 NVS Novartis $79.58 LLY Eli Lilly $301.69 Merck & Co. (MRK) Source: Atmosphere1 / Shutterstock.com Merck & Co. (NYSE: MRK ) reported better-than-expected Q2 revenue and profits thanks to Keytruda , the company’s cancer drug that binds to the PD-1 protein, helping immune cells kill cancer cells.
→ Google Traductor
(Reuters) – The United States government has sent out over 25 million of the updated COVID-19 booster shots, mostly from Pfizer/BioNTech, as production of the Moderna shot continues to ramp up, a federal health agency said on Tuesday.
→ Google Traductor
3M, Allied World Insurance, DBS Bank, Duke Energy, ENGIE, MTN Group, and Pfizer Recognized for Their Cutting-Edge Digital Transformation Achievements The Hackett Group, Inc. (NASDAQ: HCKT) today a…
→ Google Traductor
TOKYO (AP) — Asian shares mostly rose Tuesday, after Wall Street closed higher on a late buying spree following recent losses as investors await another interest rate increase by the U.S. Federal Reserve. Markets have been jittery over whether the Fed’s plan to cool the hottest U.S. inflation in four decades might be too aggressive and throw the economy into a recession by pumping the brakes on growth too hard. Japan reported that its consumer inflation jumped in August to 3.0%, its highest level since November 1991 but well below the 8% plus readings in the U.S. Core inflation excluding volatile fresh food prices climbed 2.8%. The Bank of Japan is set to have a two-day monetary policy meeting later this week, although analysts expect the central bank to stick to its easy monetary policy. “Expectations are that easy monetary policies are to remain in the upcoming meeting this week. The BOJ Gov. Haruhiko Kuroda previously mentioned that he wanted to see a ‘stable and sustainable rise’ in both wages and prices before considering any policy shift,” Yeap Jun Rong, a market strategist at IG in Singapore, said in a report.
→ Google Traductor
Fauci, Klain, Yellen, Kendi Headline Pfizer-Funded, Far-Left Conference In D.C. This Week Authored by Raheem J. Kassam and Natalie Winters via The National Pulse , Anthony Fauci is set to headline a major far-left conference whose lead sponsors include COVID-19 vaccine maker Pfizer, The National Pulse can reveal. Fauci will appear alongside race-baiter Ibram X. Kendi, White House Chief of Staff Ron Klain, Treasury Secretary Janet Yellen, and more. The September 21st to 23rd Atlantic magazine festival will take place at the Wharf in Washington, D.C., with tickets going for a cool $400.00 per person . Topics are set to include critical race theory, diversity, Ukraine, censorship, climate change, and centralizing healthcare and pandemic response control. Fauci – who has overseen most of America’s COVID-19 response in his role as the Director of the National Institute of Allergy and Infectious Diseases – has long been the subject of “fact checks” by corporate media sources such as Reuters, which deny his links with Big Pharma group Pfizer.
→ Google Traductor
The Federal Reserve was top of mind for investors Monday, with the central bank''s next policy decision – a likely 75 basis-point rate hike – due out Wednesday. This led to back-and-forth trading for much of the session, though the major market indexes ultimately ended in positive territory today. SEE MORE 16 Dividend Kings for Decades of Dividend Growth While the economic calendar is relatively thin over the next few days, Wall Street will see a round of housing data in the leadup to the Fed announcement. Today, that was the release of the National Association of Home Builders (NAHB)/Wells Fargo housing market index, which showed builder confidence fell 3 points in September to 46, its lowest level since spring 2020. This was the ninth straight monthly drop in the index, and came amid a "combination of elevated interest rates, persistent building material supply-chain disruptions and high home prices [that] continue to take a toll on affordability," the report stated. "We expect the other housing market releases this week (housing starts, existing home sales and building permits) will show similar weakness," says Raymond James economist Giampiero Fuentes. "Bad news continues to be good news for the Fed, as it indicates its tightening cycle is working to slow demand." Sign up for Kiplinger''s FREE Investing Weekly e-letter for stock, ETF and mutual fund recommendations, and other investing advice.
→ Google Traductor
Pfizer is not in a cyclical sector and it pays out a 3.48% dividend, with 12% returns over the past ten years. Click to read why I think PFE stock is a buy.
→ Google Traductor
New Jersey, USA -- ( SBWIRE ) -- 09/19/2022 -- Advance Market Analytics published a new research publication on "Bio-pharmaceuticals Market Insights, to 2027" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Bio-pharmaceuticals market was mainly driven by the increasing R&D spending across the world. Get Free Exclusive PDF Sample Copy of This Research @ https://www.advancemarketanalytics.com/sample-report/104952-global-bio-pharmaceuticals-market#utm_source=SBWireLal The Bio-pharmaceuticals Market report covers extensive analysis of the key market players, along with their business overview, expansion plans, and strategies. The key players studied in the report include: Pfizer (United States), F. Hoffmann-La Roche AG (Switzerland), AbbVie(United States), Johnson& Johnson (United States), Sanofi (France), AstraZeneca (United Kingdom), Novartis (Switzerland), Novo Nordisk (Denmark), Merck & Co., Inc. (United States), Eli Lilly and Company (United States), Bristol-Myers Squibb Company (United States), Cadila Healthcare Limited (Zydus Cadila) (India), Amgen (United States), Abbott Laboratories (United States), Biocon Ltd (India).
→ Google Traductor
Thirteen of the worlds 20 largest biopharmaceutical companies experienced more than 10% revenue growth from 2020 to 2021, according to a new report.
→ Google Traductor
RIO DE JANEIRO (Reuters) – Brazilian national health regulator Anvisa has approved the COVID-19 vaccine produced by Pfizer and BioNTech for children aged between six months and four years, the government body said in a statement Friday night.
→ Google Traductor
Brazilian national health regulator Anvisa has approved the COVID-19 vaccine produced by Pfizer and BioNTech for children aged between six months and four years, the government body said in a statement Friday night.
→ Google Traductor
Global Blood Therapeutics has several intriguing molecules that could garner blockbuster sales for Pfizer in the coming years. Read what investors need to know.
→ Google Traductor